THE ATXA TEAM
Prof. Therese Kinsella, PhD, MRIA
Founder & Chief Scientific Officer
Therese Kinsella is Professor of Biochemistry within the School of Biomolecular and Biomedical Sciences, University College Dublin. She is a leading expert in the field of prostanoid biology, focusing on the vasculature and has published extensively in this area in top journals and book chapters. As Founder of ATXA Therapeutics, Therese is an inventor on an extensive patent portfolio including the discovery of the TP antagonists currently in early clinical development at ATXA.
In recognition of her contribution to her research field, Therese has received numerous awards during her professional career including the Royal Irish Academy Medal in Biochemistry (2000); she was elected Member Royal Irish Academy (MRIA, 2006) and received the Biochemical Society (IAS) Gold Medal (2008). She has extensive expertise in securing R&D funding and management including, for example as Founder and Chief Scientific Officer at ATXA Therapeutics Ltd, securing a prestigious European Union SME-Instrument grant in 2018. Therese has also secured several commercialization-type grants from Enterprise Ireland which enabled the early stage drug-discovery and pre-clinical efficacy program that led to the development ATXA's lead drug NTP42 and to prioritization of its target market for treatment of pulmonary arterial hypertension (PAH). Since company spin-out, she has over-seen the recent granting of Orphan Medicinal Product (OMP) designation for ATXA’s NTP42 for PAH from both the EMA and the FDA.
She has also acted as expert consultant to large pharmaceutical, biotech & life science venture capital funds. Having begun her research career in industry (Guinness), Therese has a strong appreciation of the underlying processes of product/drug development, including associated-challenges.
Ivan Coulter, PhD, MBA
Chief Executive Officer
Dr Ivan Coulter joined the company as CEO in October 2018. An experienced bio-entrepreneur, prior to joining ATXA Ivan was the founder and CEO/CSO of Sigmoid Pharma Limited (now Sublimity Therapeutics). Under his leadership Sigmoid developed an innovative oral drug delivery technology, SmPill®, and progressed the clinical development of a SmPill®-enabled product through Phase II studies in moderate-severe ulcerative colitis.
During his time as CEO, Sigmoid brought in over €100M of partnership and financing into the company, including Series B financing in May 2018 and a European licensing deal with Dr Falk in 2017.
Ivan received a B.Sc. (Honours) degree and a PhD in Pharmacology from University College Dublin, and an MBA from Cornell University, USA. Ivan obtained a Certified Diploma in Accounting and Finance (C.Dip.A.F.) from the Association of Chartered Certified Accountants. Ivan is a lead inventor or co-inventor of over 20 patent applications. Ivan has been involved in several successful licensing and multi-disciplinary development collaborations with academic and industry partners and is the recipient of multiple national and international awards and grants.
Eamon Mulvaney, PhD
Dr Eamon Mulvaney joined the company in Jan 2016 as Senior Scientist and Analyst. Eamon has dedicated his PhD and post-doctoral career to research on the role of prostanoid receptors in health and disease and has been instrumental in undertaking detailed morphometric and immunohistological analyses of ATXA's lead drug NTP42 in two preclinical models of PAH, namely the Sugen-Hypoxia (SuHx) and Monocrotaline (MCT) models. He has also extensive expertise as a data analyst/biostatistician and in regulatory affairs.
Helen Reid, PhD
Dr Helen Reid has acted as lead biologist and as project leader at all stages in the development of the TP antagonists from discovery to candidate selection and development. She has over 16 years of experience in the field of prostanoid biology, with particular interests in the cardiovascular area and in the drug discovery & development process. Helen has many publications in top peer-reviewed journals in prostanoid biology area and was co-inventor with Prof Therese Kinsella in the patent series covering the novel series of TP antagonists.
Lucia Bialesova, PhD
Lucia has over 8 years experience in cell biology and in cancer research. After completing her PhD on nuclear receptors in breast cancer, she continued as a postdoc at the prestigious Karolinska Institute, Stockholm where she worked in the fields of epigenetics and DNA methylation in metabolic diseases, and on the role of Estrogen Receptor in breast cancer. After several years of experience in academia and public medical health, Lucia joined the R&D team at ATXA Therapeutics recognizing the collaborative and challenging opportunity that this role offers.
Audrey Murray, BComm, FCCA, LIB
Administrator & Relationship Manager
Audrey joined the team in October 2018. She previously acted as Project Manager on a large scale EU Interreg project (Ireland Wales Programme 2014-2020) within University College Dublin. Prior to this, Audrey has over 20 years’ experience in a banking environment in finance, relationship manager and project management roles.
Andy Baxter, PhD
Andy has held senior technical and management positions in major pharmaceutical companies (Glaxo and Pfizer, where he was involved in the initial development of Sumatriptan), emerging biotech companies (Chiroscience - Celltech) and, most recently, early-stage/small pharmaceutical companies (Arakis, Serentis and Altacor). Andy has acted as product development advisor to ATXA since spin-out in 2015 and will continue to oversee product development as the company moves into the clinical stage of its drug development programme.
Andy has >30 years’ experience in the biotechnology and pharmaceutical industry, including in discovery and development from early research through to mid-stage clinical trials. He is an inventor or co-inventor of over 60 patent applications. Andy has developed products as solid dose forms (including modified release), parental, topical, inhaled, intra-nasal, sub-lingual and transdermal patches. Andy has been successfully involved in both in-licensing and out-licensing projects and has managed collaborations between major pharmaceutical companies on a multidisciplinary level.
Adriaan Fruijtier, Masters in Pharmacy
Adriaan has held senior and management positions in Global Regulatory Affairs at Bayer AG, Wuppertal, Germany and Bayer Corporation, West Haven, CT, USA; Micromet AG, Munich, Germany; European Medicines Agency (EMA), London, UK; Novartis AG, Basel, Switzerland; Ciba-Geigy, Netherlands and Glaxo, Netherlands. As a regulatory affairs expert, Adriaan has extensive knowledge of regulatory compliance and safety assessments in Europe. Adriaan has acted as regulatory affairs advisor to ATXA since spin-out.
Dr. Luke Howard, DPhil. FRCP
Member of the Science/Clinical Advisory Board
Dr Luke Howard is a Consultant Pulmonologist and Lead Clinician for the Pulmonary Hypertension Service, Hammersmith Hospital, Imperial College Healthcare NHS Trust, UK and Honorary Senior Lecturer, National Heart & Lung Institute, Imperial College London. Dr Howard specialises in diseases of the pulmonary circulation, particularly in pulmonary hypertension and pulmonary embolism. He has a research interest in cardiopulmonary physiology and early phase clinical trials. Since spin-out, Dr Howard has acted as clinical advisor to ATXA.
Dr Alexander Rothman, MA., BM., BCh., MRes., PhD., MRCP
Member of the Science/Clinical Advisory Board
Dr Alexander Rothman is a Wellcome Trust Career Development Fellow and NIHR Clinical Lecturer in cardiology at the University of Sheffield and an Honorary Cardiology Registrar at Sheffield Teaching Hospitals NHS Trust, UK. Dr Rothman has significant interest in the pathology and treatment of cardiovascular diseases and has been closely involved in studies investigating new therapies and devices for the treatment of pulmonary arterial hypertension, atherosclerosis and heart failure.
Alex’s current work focuses on the pathology of pulmonary arterial hypertension and the development of novel therapeutic strategies. Since spin-out, Dr Rothman has acted as scientific and clinical advisor to ATXA.
Further detail on the members of our Clinical Team will be available shortly.